Evidence map›Paper›PMID 39428542›Full record

ArticleScientific reports2024

Hyperbaric oxygen therapy in the treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Joana Arana Ribeiro, Diogo Alpuim Costa, Clara Gaio-Lima, José Guilherme Gonçalves-Nobre, Inês Portugal Rodrigues, Mariana Trigo Miranda, Carlos Pinho Vaz, Carla D'Espiney Amaro, Óscar Camacho

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Joana Arana Ribeiro *Pulmonology Department, Unidade Local de Saúde da Guarda, E. P. E., Avenida Rainha Dona Amélia 19, Guarda, 6300-749, Portugal. joana.s.ribeiro@ulsguarda.min-saude.pt.
Diogo Alpuim Costa *Medical Oncology Department, Hospital de Cascais, Alcabideche, Cascais, Portugal.
Clara Gaio-LimaAnesthesiology Department, Unidade Local de Saúde de Matosinhos, E. P. E, Porto, Portugal.
José Guilherme Gonçalves-NobreMedical Oncology Department, Hospital Garcia de Orta, E. P. E, Almada, Portugal.
Inês Portugal RodriguesAnesthesiology Department, Unidade Local de Saúde de Matosinhos, E. P. E, Porto, Portugal.
Mariana Trigo MirandaHematology Department, Centro Hospitalar Tondela Viseu, E. P. E, Viseu, Portugal.
Carlos Pinho VazBone Marrow Transplantation Unit, Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E, Porto, Portugal.
Carla D'Espiney AmaroHematology and Oncology Department, CUF Oncologia, Lisbon, Portugal.
Óscar CamachoAnesthesiology Department, Unidade Local de Saúde de Matosinhos, E. P. E, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHemorrhagic cystitis (HC) is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT), characterized by inflammation and bleeding of the bladder. Hyperbaric oxygen therapy (HBOT) has been shown to be effective in the treatment of radiation-induced HC. However, the optimal treatment for HC after allogeneic HSCT has not yet been established. Furthermore, limited research has been conducted on the use of HBOT in this setting. This study aimed to evaluate the effectiveness and safety of HBOT in patients with late-onset HC after allogeneic HSCT.

methodsTwenty-five-year (1998-2022) retrospective analysis performed in all consecutive patients with confirmed late-onset HC after allogeneic HSCT treated with HBOT at two centers in Portugal. Medical records were reviewed for clinical and laboratory features, primary indications for allogeneic HSCT, conditioning regimen, and treatment strategies for HC. Patients received 100% oxygen at 2.1-2.5 atmosphere absolute pressure (ATA) for 70-90-minute periods, once daily, five times per week. Complete clinical response was defined as the absence of macroscopic hematuria sustained for at least 2 weeks, and partial response was described as a downgrading in the severity of HC. Statistical significance was considered for values of p < 0.05.

resultsThe sample included 61 patients with a mean age of 28.0 (SD 14.2) years, 33 males. Complete response was achieved in 72.1% (n = 44) of patients and partial response in 14.8% (n = 9). Concerning patients with a complete response, the median number of HBOT sessions was 15.5 sessions (IQR 10.0-26.8). Patients treated with 10 or more sessions of HBOT had a higher rate of complete or partial response (OR 12.5, 95%CI 1.9-83.2, p-value < 0.05). There was no response in 8 (13.1%) patients, and 6 interrupted the treatments early. Only 2 patients suspended the HBOT due to a lack of clinical benefit.

conclusionOur study supports using of HBOT as an adjunctive treatment for late-onset HC after allogeneic HSCT. Furthermore, 10 or more HBOT sessions delivered seem to impact the rate of HC resolution. Prospective, randomized, and well-controlled trials are needed to establish HBOT's definitive efficacy and safety.

Indexed as

CystitisHematopoietic Stem Cell TransplantationHyperbaric OxygenationTransplantation, HomologousAdolescentAdultAgedCystitis, HemorrhagicFemaleHemorrhageHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung Adult

Identifiers

PMID39428542
PMCPMC11491472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.